Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 2
2019 6
2020 6
2021 3
2022 5
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
MiRNAs in renal cell carcinoma.
Miranda-Poma J, Trilla-Fuertes L, López-Camacho E, Zapater-Moros A, López-Vacas R, Lumbreras-Herrera MI, Pertejo-Fernandez A, Fresno-Vara JÁ, Espinosa-Arranz E, Gámez-Pozo A, Pinto-Marín Á. Miranda-Poma J, et al. Among authors: trilla fuertes l. Clin Transl Oncol. 2022 Nov;24(11):2055-2063. doi: 10.1007/s12094-022-02866-z. Epub 2022 Jun 21. Clin Transl Oncol. 2022. PMID: 35729452 Review.
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma.
Trilla-Fuertes L, Gámez-Pozo A, Nogué M, Busquier I, Arias F, López-Campos F, Fernández-Montes A, Ruiz A, Velázquez C, Martín-Bravo C, Pérez-Ruiz E, Asensio E, Hernández-Yagüe X, Rodrigues A, Ghanem I, López-Vacas R, Hafez A, Arias P, Dapía I, Solís M, Dittmann A, Ramos R, Llorens C, Maurel J, Campos-Barros Á, Fresno Vara JÁ, Feliu J. Trilla-Fuertes L, et al. Cancer. 2023 Aug 15;129(16):2581-2592. doi: 10.1002/cncr.34797. Epub 2023 Apr 25. Cancer. 2023. PMID: 37096763
Proteomics Characterization of Clear Cell Renal Cell Carcinoma.
Miranda-Poma J, Trilla-Fuertes L, López-Vacas R, López-Camacho E, García-Fernández E, Pertejo A, Lumbreras-Herrera MI, Zapater-Moros A, Díaz-Almirón M, Dittmann A, Fresno Vara JÁ, Espinosa E, González-Peramato P, Pinto-Marín Á, Gámez-Pozo A. Miranda-Poma J, et al. Among authors: trilla fuertes l. J Clin Med. 2023 Jan 3;12(1):384. doi: 10.3390/jcm12010384. J Clin Med. 2023. PMID: 36615183 Free PMC article.
Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy.
Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, Trilla-Fuertes L, Rubiolo JA, Batres-Ramos S, Vallespinos M, González-Páramos C, Rodríguez J, Gámez-Pozo A, Vara JÁF, Fernández SF, Berlinches AB, Moreno-Mata N, Redondo AMT, Carrato A, Hermann PC, Sánchez L, Torrente S, Fernández-Moreno MÁ, Mascareñas JL, Sainz B Jr. Alcalá S, et al. Among authors: trilla fuertes l. J Exp Clin Cancer Res. 2024 Jan 27;43(1):33. doi: 10.1186/s13046-023-02931-7. J Exp Clin Cancer Res. 2024. PMID: 38281027 Free PMC article.
Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer.
López-Camacho E, Trilla-Fuertes L, Gámez-Pozo A, Dapía I, López-Vacas R, Zapater-Moros A, Lumbreras-Herrera MI, Arias P, Zamora P, Vara JÁF, Espinosa E. López-Camacho E, et al. Among authors: trilla fuertes l. Biomed Pharmacother. 2022 May;149:112844. doi: 10.1016/j.biopha.2022.112844. Epub 2022 Mar 23. Biomed Pharmacother. 2022. PMID: 35339109 Free article.
Bayesian networks established functional differences between breast cancer subtypes.
Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, López-Vacas R, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Ferrer-Gómez M, Navarro H, Nanni P, Zamora P, Espinosa E, Maín P, Fresno Vara JÁ. Trilla-Fuertes L, et al. PLoS One. 2020 Jun 11;15(6):e0234752. doi: 10.1371/journal.pone.0234752. eCollection 2020. PLoS One. 2020. PMID: 32525929 Free PMC article.
Molecular characterization of triple negative breast cancer formaldehyde-fixed paraffin-embedded samples by data-independent acquisition proteomics.
García-Adrián S, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, López-Vacas R, López-Camacho E, Zapater-Moros A, Lumbreras-Herrera MI, Hardisson D, Yébenes L, Zamora P, Sabidó E, Fresno Vara JÁ, Espinosa E. García-Adrián S, et al. Among authors: trilla fuertes l. Proteomics. 2022 Feb;22(3):e2100110. doi: 10.1002/pmic.202100110. Epub 2021 Oct 27. Proteomics. 2022. PMID: 34624180
Melanoma proteomics suggests functional differences related to mutational status.
Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Fortes C, Ferrer-Gómez M, López-Vacas R, Parra Blanco V, Márquez-Rodas I, Soria A, Fresno Vara JÁ, Espinosa E. Trilla-Fuertes L, et al. Sci Rep. 2019 May 10;9(1):7217. doi: 10.1038/s41598-019-43512-z. Sci Rep. 2019. PMID: 31076580 Free PMC article.
Metabolomics unravels subtype-specific characteristics related to neoadjuvant therapy response in breast cancer patients.
Zapater-Moros A, Díaz-Beltrán L, Gámez-Pozo A, Trilla-Fuertes L, Lumbreras-Herrera MI, López-Camacho E, González-Olmedo C, Espinosa E, Zamora P, Sánchez-Rovira P, Fresno Vara JÁ. Zapater-Moros A, et al. Among authors: trilla fuertes l. Metabolomics. 2023 Jun 21;19(7):60. doi: 10.1007/s11306-023-02024-8. Metabolomics. 2023. PMID: 37344702
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.
Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, López-Vacas R, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez-Ruiz E, González-Cao M, Oramas J, Magdaleno A, Fra J, Martín-Carnicero A, Corral M, Puértolas T, Ramos-Ruiz R, Dittmann A, Nanni P, Fresno Vara JÁ, Espinosa E. Trilla-Fuertes L, et al. Cancers (Basel). 2023 Sep 3;15(17):4407. doi: 10.3390/cancers15174407. Cancers (Basel). 2023. PMID: 37686682 Free PMC article.
34 results